Dna Biomed Solns Stock Cash Per Share
| DNA Stock | ILS 88.60 1.60 1.84% |
DNA Biomed Solns fundamentals help investors to digest information that contributes to DNA Biomed's financial success or failures. It also enables traders to predict the movement of DNA Stock. The fundamental analysis module provides a way to measure DNA Biomed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DNA Biomed stock.
DNA |
DNA Biomed Solns Company Cash Per Share Analysis
DNA Biomed's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, DNA Biomed Solns has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Electronic Equipment, Instruments & Components sector and 100.0% lower than that of the Information Technology industry. The cash per share for all Israel stocks is 100.0% higher than that of the company.
DNA Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses DNA Biomed's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of DNA Biomed could also be used in its relative valuation, which is a method of valuing DNA Biomed by comparing valuation metrics of similar companies.DNA Biomed is currently under evaluation in cash per share category among its peers.
DNA Fundamentals
| Return On Equity | -0.25 | |||
| Return On Asset | -0.0375 | |||
| Current Valuation | 59.57 M | |||
| Shares Outstanding | 123.16 M | |||
| Shares Owned By Insiders | 54.87 % | |||
| Price To Earning | 22.59 X | |||
| Price To Book | 0.95 X | |||
| EBITDA | 18.42 M | |||
| Net Income | 18.37 M | |||
| Cash And Equivalents | 492 K | |||
| Current Ratio | 0.03 X | |||
| Book Value Per Share | 0.79 X | |||
| Cash Flow From Operations | (2.33 M) | |||
| Earnings Per Share | 0.21 X | |||
| Number Of Employees | 11 | |||
| Beta | 0.31 | |||
| Market Capitalization | 86.46 M | |||
| Total Asset | 54.62 M | |||
| Retained Earnings | (139 M) | |||
| Working Capital | 18 M | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
| Z Score | -2.8 | |||
| Net Asset | 54.62 M |
About DNA Biomed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze DNA Biomed Solns's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DNA Biomed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DNA Biomed Solns based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in DNA Stock
DNA Biomed financial ratios help investors to determine whether DNA Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in DNA with respect to the benefits of owning DNA Biomed security.